{"id":"W4280517583","doi":"10.1016/j.jogc.2022.02.103","title":"A Phase-3, Randomized, Placebo-Controlled, 12-Week, Double-Blind Study to Assess Efficacy and Safety of Fezolinetant, a Neurokinin-3 Receptor Antagonist, in Women with Moderate-to-Severe Vasomotor Symptoms Associated with Menopause","year":2022,"lang":"en","type":"article","venue":"Journal of Obstetrics and Gynaecology Canada","topic":"Menopause: Health Impacts and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Vasomotor; Placebo; Antagonist; Randomized controlled trial; Double blind; Receptor antagonist; Internal medicine; Pharmacology; Receptor; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00252269,0.001793972,0.00534261,0.000675264,0.001233467,0.00107039,0.001458858,0.003157308,0.0077591],"category_scores_gemma":[0.002866725,0.001280563,0.002176775,0.0006126787,0.002436693,0.001529235,0.000503032,0.004131525,0.001327676],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007691958,"about_ca_system_score_gemma":0.002336568,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00201909,"about_ca_topic_score_gemma":0.004802541,"domain_scores_codex":[0.9990959,0.0003964118,0.00006986429,0.0001911903,0.00007113497,0.0001754993],"domain_scores_gemma":[0.9977818,0.0006665918,0.000354431,0.0002491552,0.0001943112,0.0007536109],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9811655,0.01029937,0.0002229435,0.0003074236,0.0002910934,0.00002257957,0.00005224703,0.0001076412,0.002626932,0.00004030625,0.0003246681,0.004539219],"study_design_scores_gemma":[0.9582592,0.04040201,0.0007360766,0.000009433859,0.0001035127,0.00001016605,0.00001124999,0.00009585615,0.000157594,0.00004948389,0.0001569191,0.000008424379],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9753944,0.003287259,0.001656418,0.0008085145,0.0008495803,0.01348546,0.001988194,0.0003237848,0.002206479],"genre_scores_gemma":[0.9646304,0.002649047,0.004662676,0.002951509,0.0009992381,0.0171574,0.001889969,0.00008890141,0.00497075],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0077591,"threshold_uncertainty_score":0.02595675,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02916318352573144,"score_gpt":0.2913229077599823,"score_spread":0.2621597242342508,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}